openPR Logo
Press release

Myositis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Corbus Pharmaceuticals, Janssen, Pfizer, Abcuro, Orphazyme, ImmunoForge, Merck, JN Biosciences, Bristol-Myers Squibb, Kezar Life Sciences

07-17-2023 07:36 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Myositis Pipeline Assessment (2023) Covering Clinical Trials,

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Myositis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Myositis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myositis Therapeutics Market.

The report provides a detailed description of the Myositis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Myositis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myositis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Myositis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myositis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Myositis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Myositis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Myositis Therapeutics Domain:
https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Myositis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Myositis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myositis Therapeutics Analysis
There are approx. 20+ key companies developing therapies for Myositis. Currently, Corbus Pharmaceuticals is leading the therapeutics market with its Myositis drug candidates in the most advanced stage of clinical development.

Myositis Companies in the Therapeutics Market Include:
• Corbus Pharmaceuticals
• Janssen Research & Development, LLC
• Pfizer
• Abcuro, Inc.
• Orphazyme
• Bristol-Myers Squibb
• Kezar Life Sciences, Inc.
• Horizon Therapeutics
• Paean Biotechnology Inc.
• Alexion Pharmaceuticals
• ImmunoForge
• JN Biosciences
• Merck KGaA
And Many Others

Emerging and Marketed Myositis Therapies Covered in the Report Include:
• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC
And Many More

Get an in-depth Assessment of the Emerging Therapies and Myositis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Myositis Current Treatment Patterns
4. Myositis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myositis Late-Stage Products (Phase-III)
7. Myositis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myositis Discontinued Products
13. Myositis Product Profiles
14. Myositis Companies
15. Myositis Drugs
16. Dormant and Discontinued Products
17. Myositis Unmet Needs
18. Myositis Future Perspectives
19. Myositis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market

Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market

Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market

Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myositis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Corbus Pharmaceuticals, Janssen, Pfizer, Abcuro, Orphazyme, ImmunoForge, Merck, JN Biosciences, Bristol-Myers Squibb, Kezar Life Sciences here

News-ID: 3134170 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Myositis

Inflammatory Myositis Market Massive Growth opportunity Ahead
Introduction Inflammatory myositis is a group of rare autoimmune disorders characterized by chronic inflammation of skeletal muscles, leading to progressive muscle weakness, fatigue, and functional disability. The spectrum includes polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and overlap syndromes. These disorders can also involve other organs, most notably the lungs (interstitial lung disease), skin, heart, and joints, complicating disease management. Historically, corticosteroids and conventional immunosuppressants have formed
Idiopathic Inflammatory Myositis Market Growth, Trends, Consumer Demand and Key …
Introduction Idiopathic Inflammatory Myositis (IIM) is a rare group of autoimmune muscle diseases characterized by chronic inflammation of skeletal muscles, leading to progressive weakness, fatigue, and in severe cases, disability. The group includes dermatomyositis (DM), polymyositis (PM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and antisynthetase syndrome. IIM can also involve systemic complications such as interstitial lung disease (ILD), cardiac dysfunction, and malignancy association, making management highly complex. Historically, treatment relied
Inclusion Body Myositis Market: A Guide to Understanding the Process
The global Inclusion Body Myositis (IBM) market is projected to reach approximately USD 231.4 million by 2033, growing at a CAGR of 8.7% from 2024 to 2033. Inclusion Body Myositis Market Overview The Inclusion Body Myositis market is growing steadily due to increasing recognition and diagnosis of this rare neuromuscular disorder. Advances in therapeutic research focusing on inflammation and muscle degeneration are driving the development of targeted treatments. Rising patient awareness and
Myositis Clinical Trials, Pipeline Insights, and Companies 2024
DelveInsight's, "Myositis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent advances in Myositis Treatment
Global Necrotizing Autoimmune Myositis Market - Opportunities & Forecasts, 2020- …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global necrotizing autoimmune myositis market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future. Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able
Inclusion Body Myositis (IBM) - Pipeline Review And Industry Insight Report 2017
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and